Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 3rd May 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,827,289 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Kallelse till årsstämma i Flowscape Technology AB (publ)

Aktieägarna i Flowscape Technology AB (publ), org.nr 556725-4866 (”Bolaget”), kallas härmed till årsstämma onsdagen den 1 juni 2022 kl. 17.00 i Bolagets lokaler på Saltmätargatan 8 i Stockholm.Aktieägare som vill delta i stämman ska dels vara införd i den av Euroclear Sweden AB förda aktieboken måndagen den 23 maj 2022, dels anmäla sitt deltagande till Bolaget senast onsdagen den 25 maj 2022, per post till adress Flowscape Technology AB, Saltmätargatan 8, 113 59 Stockholm, eller per e-post till info@flowscapesolutions.com. Vid anmälan anges namn, adress, telefonnummer, person- eller

Idogen publishes interim report for 1 January – 31 March 2022

Idogen AB's interim report for January to March 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/   First quarter (January-March 2022) • Other operating income amounted to KSEK 0 (1,679) • Operating loss was KSEK -10,712 (-10,651) • Loss for the quarter totalled KSEK -10,692 (-10,531) • Cash flow from operating activities was KSEK -18,061 (-9,952) • Loss per share before dilution was SEK -0.25 (-0.58). Loss per share after dilution was SEK -0.25 (-0.58)   Significant events in the first quarter • Idogen submits an

PONSSE Scorpion’s Future Cabin received the Fennia Prize design award

One of the most significant design awards in Finland was given to PONSSE Scorpion’s Future Cabin. In addition to Ponsse, Fennia Prize recognitions were given to Posti Group Corporation, Nokian Heavy Tyres Ltd and Myssyfarmi Oy.In the design of Future Cabin, the Fennia Prize jury appreciated research and development based on customer feedback, focusing on the forest machine operator’s well-being and comfort, as well as improved working conditions. Other criteria included Ponsse’s sustainable solutions that support forest health and the environment.“Customer feedback has always been

Scania Interim Report January–March 2022

The first quarter of the year was characterised by a high degree of uncertainty due to the changing global macroeconomic and geopolitical situation. However, the level of activity in Scania’s key markets remains high and demand for trucks is strong.Summary of the first three months of 2022•    Net sales decreased by 3 percent to SEK 34,757 m. (35,708)•    Operating income decreased by 44 percent to SEK 2,607 m. (4,657)•    Operating margin amounted to 7.5 percent (13.0)•    Cash flow amounted to SEK -1,184 m. (2,862) in Vehicles and Services Comments by Christian Levin, President

Fennia Prize 22: PRH gives an honourable mention to two companies

In the Fennia Prize 22 design competition, the Finnish Patent and Registration Office (PRH) awarded an honourable mention and a prize of EUR 5,000 for the successful use of intellectual property rights (IPR). The honourable mention for IPR Excellence went to two companies: Genelec Oy and Mysoda Oy.Genelec Oy For more than 20 years, industrial design has been important for loudspeaker manufacturer Genelec. Design is a strategic aspect of the company’s operations. In terms of acoustic products such as loudspeakers, design is important not only for their appearance but also for their

Nordic Capital announces strategic investment in German IoT and wearable technology disruptor ProGlove

· The partnership will accelerate the company’s rapid global growth in the large and growing market for wearable technology and software solutions  · Nordic Capital will support ProGlove and its unique, human centered solutions to improve shopfloor processes and achieve substantial efficiency gainsNordic Capital, a leading European private equity investor, has signed an agreement to become the majority owner of the German-based Industrial Internet of Things (“IoT”) company ProGlove. ProGlove is a disruptive technology leader for a smarter workforce. In close partnership with ProGlove’s

Urban centre Lippulaiva becomes the world's first centre to be awarded Smart Building’s Gold certificate

CITYCON OYJ Corporate Press Release 4 May 2022 Urban centre Lippulaiva, which was opened at the end of March in Espoonlahti near Helsinki, becomes the world's first centre to be awarded Smart Building’s Gold certificate. Lippulaiva’s construction and design were also recognised by way of another significant sustainability certification, the LEED Gold environmental certificate. Smart Building Certification has granted a Smart Building Gold certificate for the development of urban centre Lippulaiva. Lippulaiva will become the world's first centre to be awarded Smart Building’s

Imfinzi combo granted Priority Review for BTC

4 May 2022 07:00 BST Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial First Phase III trial in this setting to show improved overall survival with an immunotherapy added to chemotherapy over standard-of-care chemotherapy alone AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or

TactoTek® licensee Nanogate is ready for IMSE® Manufacturing to benefit Home Appliance, Consumer Electronics, Medical, and Automotive Markets

OULU, FINLAND/ FOHNSDORF, AUSTRIA – (4th May 2022) – TactoTek, the global leader in developing and industrializing in-mold structural electronics (IMSE) technology, announces that its licensee, Nanogate, a leading global specialist for design-oriented high-tech surfaces and components, is ready to mass produce IMSE parts. Nanogate recently completed the IMSE Builder® technology transfer and has verified IMSE manufacturing capabilities.TactoTek’s IMSE Builder includes intellectual property rights, know-how, and instruction for IMSE manufacturing, testing, and quality assurance, as well as

Eltel Group: Interim report January–March 2022

January–March 2022 · Net sales EUR 184.0 million (182.0). Total growth 1.1% and organic growth1) in segments 0.2% · Operative EBITA2) EUR -2.4 million (-0.7) and operative EBITA margin -1.3% (-0.4) · Operative EBITA2) in segments EUR 0.7 million (2.4) and operative EBITA margin in segments 0.4% (1.5) · Operating result (EBIT) EUR -2.5 million (-0.8) and EBIT margin -1.4% (-0.4) · Net result EUR -4.4 million (-2.7) · Earnings per share EUR -0.03 (-0.02), basic and diluted · Cash flow from operating activities EUR -8.8 million (-17.4) · Net debt3) EUR 135.8 million (

Interim report 1 January – 31 March 2022

First QUARTER (1 January – 31 March 2022) · Net sales for the quarter amounted to MSEK 88 (47). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 61 (23). · Operating profit (EBIT) was MSEK 46 (7). · Profit/loss before tax, before items affecting comparability, was MSEK 42 (4) and after items affecting comparability MSEK 37 (-4). · Profit/loss after tax totalled MSEK 37 (-4), corresponding to SEK 0.90 (-0.12) per share. · Operating cash flow was MSEK 67 (15) and cash flow after investments amounted to MSEK 47 (8). · Production generated

Nanoform launches “STARMAP[®] Online” placing AI-power at the fingertips of medicine developers

Press release Nanoform Finland Plc May 4[th], 2022 09:00 a.m. Finnish time / 08:00 a.m. Swedish time Nanoform launches “STARMAP[®] Online” placing AI-power at the fingertips of medicine developers Helsinki, Finland – Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has launched its sparse-data AI solution (STARMAP[®] Online) as a secure online portal for direct use by its current and future partners. Since its inception in 2020, STARMAP[® ]has been actively used by Nanoform to provide its clients with a confident

INTERIM REPORT FIRST QUARTER 2022

RECORD HIGH REVENUES OF €46.3 MILLION IN Q1 2022· Revenues increased by 31.7% to €46.3 million (35.2).       · EBITDA increased by 18.7 % to €8.2 million (6.9).               · The EBITDA margin amounted to 17.8% (19.7%).                · EBIT increased by 13.6% to € 5.6 million (4.9).     · Earnings after tax increased by 4.7% to €4.8 million (4.5).              · Earnings per share amounted to €0.10 (0.10) *B2C as discontinued operations in Q1 2021 and based on net royalties during Q1 2022. SIGNIFICANT EVENTS IN THE QUARTER AND AFTER THE END OF THE QUARTER · GLI-

Reminder: Invitation to presentation of Orkla’s first quarter 2022 results, Thursday 5 May

Orkla will report its first quarter 2022 results on Thursday, 5 May 2022 at 7.00 a.m. CET.The quarterly report and the presentation material will be available at this time at: https://investors.orkla.com.The quarterly results will be presented at 8.00 a.m. CET at the Orkla House, Drammensveien 149, Oslo. The presentation and subsequent Q&A session will be held in English and may be viewed in a live webcast at https://investors.orkla.com (direct link: https://events.webcast.no/orkla-asa-1/presentations/yVMiN2YavJkVNMeJy5LP) or followed by telephone (listen only): Dial-in details:

Publication of Orthex’s Q1 Interim report on 11 May 2022 and invitation to the result presentation on the same day

Orthex Corporation, Press release, 4 May 2022 at 9.00 a.m. EESTOrthex will publish its Interim report for the period of January−March 2022 on Wednesday, 11 May 2022 at around 09:00 a.m. EEST.Orthex’s CEO Alexander Rosenlew and CFO Saara Mäkelä will present the Interim report on the same day at 11:00 a.m. EEST in a webcast. The webcast can be joined through this link.  The webcast presentation will be held in English.Q&A:Questions to the management can be sent through the meeting chat.Presentation material:The

CONCENTRIC INTERIM REPORT JANUARY – MARCH 2022

FIRST QUARTER 2022 · Net sales: MSEK 934 (432) – reported sales were up +116% year-on year. After adjusting for the impact of currency (+18%) and EMP (+74%), sales on a like for like basis, in constant currency year-on-year were up +24%. · Operating income: Operating income was MSEK 166 (95) generating an Operating margin of 17.8% (21.9). The quarter includes a full three months of trading for EMP, diluting Operating margin. · Net income for the period: MSEK 130 (72); basic EPS of SEK 3.43 (1.90) and diluted EPS of SEK 3.41 (1.89). · Cash flow from operating activities: Cash

SaltX Technology Holding AB Interim report 1 2022

FINANCIAL EVENTS  First quarter  · Net sales amounted to MSEK 0.1 (0.0)  · Operating profit/loss (EBIT) totaled MSEK -12.4 (-8.1)  · Cash flow from operating activities amounted to MSEK -12.3 (-7.8)  · Earnings per share before and after dilution amounted to SEK -0.14 (-0.11)   SIGNIFICANT EVENTS  First quarter  · SaltX presented successful results for the charging reactor in Bollmora  · SaltX and Alfa Laval in collaboration to streamline energy storage – EnerStore  · SaltX's new innovation - charging reactor with several uses   After the end of the

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

SynAct Pharma AB (“SynAct”) today announce that the company´s pharmacokinetic study on new tablet formulations of AP1189 has been successfully completed. The data confirms the tablet formulation as superior to, the until now used, AP1189 suspension. Further clinical development of AP1189 will be conducted using the new tablet.The study was setup with three parts. In part 1 of the study, AP1189 formulated as fast release tablets, was tested in 12 healthy volunteers in cross over design with the previously used AP1189 suspension as control. The pharmacokinetic profile of the tablets was

Oncopeptides publishes Q1 report 2022

STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the first quarter 2022.“It is with growing enthusiasm and confidence in our data that we enter into 2022”, says Jakob Lindberg, CEO of Oncopeptides. “The first quarter has been characterized by regulatory interactions in Europe and the US. The outcome of these interactions will have significant implications on the future direction of the Company, and our ability to continue

Storebrand Boligkreditt AS: Interim report Q1 2022

Storebrand Boligkreditt AS is a wholly owned subsidiary of the listed company Storebrand ASA. For information about the Storebrand Group's Q1 2022 result and Balance sheet statement, please refer to the Storebrand Group Q1 2022 interim report. Storebrand Boligkreditt AS interim report for Q1 2022 is attached.This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Storebrand Livsforsikring AS: Interim report Q1 2022

Storebrand Livsforsikring AS is a wholly owned subsidiary of the listed company Storebrand ASA. For information about the Storebrand Group's Q1 2022 result and Balance sheet statement, please refer to the Storebrand Group Q1 2022 interim report. Storebrand Livsforsikring AS interim report for Q1 2022 is attached.This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Interim Report 1 for the Period January 1 - March 31, 2022

HEATPOWER 300 MARINE - REDUCED CO\2\ EMISSIONS AND SHORTER PAYBACK TIME During the quarter, Climeon's HeatPower was brought into operation on Virgin Voyage's third cruise ship, Resilient Lady, as well as two HeatPower modules in geothermal plants in Japan. The installation work in other projects continued according to plan. The development of the new product HeatPower 300, a platform that is initially optimized for the marine market, was on schedule and the product could be presented to potential customers in connection with the trade fair Seatrade Cruise Global in Miami, USA at the end

Three month report, January–March 2022

January-March 2022 compared to January-March 2021Highlights according to segment reporting: • Revenue amounted to SEK 37.8 billion (34.4); adjusted for currency effects revenue increased 3 percent. • Operating income amounted to SEK 1.9 billion (2.3); adjusted for currency effects operating income decreased 23 percent. • Earnings per share amounted to SEK 3.62 (4.59). • Operating cash flow from operations amounted to SEK -2.8 billion (3.3), according to IFRS. • Adjusted interest-bearing net receivables(+)/net debt(-) totaled SEK 15.4 billion (December 31, 2021: 17.7),

There are no items matching the current filter
There are no more items matching the current filter
Back to top